Your browser doesn't support javascript.
loading
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi, Alain P; Tsai, Katy K; Shoushtari, Alexander N; Munhoz, Rodrigo R; Eroglu, Zeynep; Piulats, Josep M; Ott, Patrick A; Johnson, Douglas B; Hwang, Jimmy; Daud, Adil I; Sosman, Jeffrey A; Carvajal, Richard D; Chmielowski, Bartosz; Postow, Michael A; Weber, Jeffrey S; Sullivan, Ryan J.
Afiliación
  • Algazi AP; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. alain.algazi@ucsf.edu.
  • Tsai KK; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Shoushtari AN; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Munhoz RR; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Eroglu Z; Moffitt Cancer Center, Tampa, Florida.
  • Piulats JM; Spanish Melanoma Multidisciplinary Group, Barcelona, Spain.
  • Ott PA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Johnson DB; Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
  • Hwang J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Daud AI; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Sosman JA; Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
  • Carvajal RD; Columbia University Medical Center, New York, New York.
  • Chmielowski B; Johansson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.
  • Postow MA; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Weber JS; Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
  • Sullivan RJ; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Cancer ; 122(21): 3344-3353, 2016 Nov 15.
Article en En | MEDLINE | ID: mdl-27533448
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Úvea / Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 / Melanoma / Membrana Mucosa Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Úvea / Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 / Melanoma / Membrana Mucosa Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2016 Tipo del documento: Article